PLoS ONE · 2020 · 15 citations · 22 references
Veterinary MedicineInfectious DiseasesImmunizationMedical EthicsVaccinologyClinical Trial EthicsClinical TrialsClinical Vaccine TrialsClinical Trial CompensationCoercive PressuresCompensation For Research ParticipationCompensation In Clinical TrialsEbola VaccinesTransactions
Millions of volunteers take part in clinical trials every year. This is unsurprising, given that clinical trials are often much more lucrative than other types of unskilled work. When clinical trials offer very high pay, however, some people consider them repugnant. To understand why, we asked 1,428 respondents to evaluate a hypothetical medical trial for a new Ebola vaccine offering three different payment amounts. Some respondents (27%) used very high pay (£10,000) as a cue to infer the potential risks the clinical trial posed. These respondents were also concerned that offering £10,000 was coercive- simply too profitable to pass up. Both perceived risk and coercion in high-paying clinical trials shape how people evaluate these trials. This result was robust within and between respondents. The link between risk and repugnance may generalize to other markets in which parties are partially remunerated for the risk they take and contributes to a more complete understanding of why some market transactions appear repugnant.
22
Measuring Risk Literacy: The Berlin Numeracy Test
Edward T. Cokely, Mirta Galešić, Eric Schulz et al. · Judgment and Decision Making · 2012 · 773 citations · Full text
Payment of clinical research subjects
Christine Grady · Journal of Clinical Investigation · 2005 · 359 citations · Full text